Elevated pre-transplant pulmonary vascular resistance is not associated with mortality in children without congenital heart disease: A multicenter study

Marc E. Richmond, Yuk M. Law, Bibhuti B. Das, Melanie D. Everitt, Manisha Kukreja, David C. Naftel, Mariska S. Kemna, Heather T. Henderson, Kimberly Beddows, F. Jay Fricker, William T. Mahle

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Background Traditionally, an elevated pulmonary vascular resistance index (PVRI) has been a relative contraindication to pediatric orthotopic heart transplantation. This study examined the risk of elevated pre-transplant PVRI on early (30-day) and intermediate-term mortality in pediatric heart transplant recipients without congenital heart disease (CHD). Methods A review of the prospective multicenter Pediatric Heart Transplant Study registry identified all patients without CHD in whom a pre-transplant PVRI was recorded. Of 35 participating centers, 29 reported heart transplants in children with a markedly elevated PVRI (> 5 WU × m2, corresponding to the highest quartile). Multiphase parametric analysis was performed, adjusting for potential risk factors to assess the association of PVRI with early and intermediate-term mortality. Results Between 1993 and 2011, 1,909 children without CHD underwent heart transplantation at a median age of 9.7 years (range, 1.6 months-18 years). Of those, 795 (42%) had a recorded or calculable pre-transplant PVRI, and PVRI > 5 WU × m2 was present in 193 patients (24%). For all recipients, median pre-transplant PVRI was 3.15 WU × m2 (range, 0.4-23 WU × m2); 2.8 WU × m2 in infants < 1 year, 3.5 WU × m2 in patients aged 1 to 10 years, and 3.0 WU × m2 in patients aged > 10 years (p = 0.03). Multivariable hazard analysis controlling for graft ischemic time and pre-transplant ventilation showed no association of elevated PVRI with early mortality (relative risk, 1.2; p = 0.66), nor with intermediate mortality when controlled for year of transplant, age, race, and pre-sensitization (relative risk, 0.7; p = 0.27). Conclusions Elevation of PVRI did not affect post-transplant survival in this large, multicenter cohort of pediatric heart transplant recipients without CHD, suggesting that the barrier of elevated PVRI can be successfully overcome in this population.

Original languageEnglish (US)
Pages (from-to)448-456
Number of pages9
JournalJournal of Heart and Lung Transplantation
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2015

Keywords

  • cardiomyopathy
  • heart transplant outcome
  • mortality
  • pediatric
  • pulmonary vascular resistance index

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation

Fingerprint Dive into the research topics of 'Elevated pre-transplant pulmonary vascular resistance is not associated with mortality in children without congenital heart disease: A multicenter study'. Together they form a unique fingerprint.

  • Cite this

    Richmond, M. E., Law, Y. M., Das, B. B., Everitt, M. D., Kukreja, M., Naftel, D. C., Kemna, M. S., Henderson, H. T., Beddows, K., Fricker, F. J., & Mahle, W. T. (2015). Elevated pre-transplant pulmonary vascular resistance is not associated with mortality in children without congenital heart disease: A multicenter study. Journal of Heart and Lung Transplantation, 34(3), 448-456. https://doi.org/10.1016/j.healun.2014.04.021